123 Results for "

rankl

" in MedChemExpress (MCE) Product Catalog:
Products (123)

123 Results for "rankl" in MCE Product Catalog:

24
24 Publications Verification
Cat. No.: HY-N0751
CAS No.: 27740-01-8
Scutellarin, an active flavone isolated from Scutellaria baicalensis, can down-regulates the STAT3/Girdin/Akt signaling in HCC cells, and inhibits RANKL-mediated MAPK and NF-κB signaling pathway in osteoclasts. Scutellarin is active against HIV-1IIIB, HIV-1(74V) and HIV-1KM018 with EC50s of 26 μM, 253 μM and 136 μM, respectively.
loading...
    loading...
17
17 Cited Publications
Cat. No.: HY-P7425
Purity:  ≥ 95%, as determined by reducing SDS-PAGE.
Synonyms: rMuRANK L/TNFSF11; TRANCE; CD254
Species:  
Source:  
loading...
    loading...
11
11 Cited Publications
Cat. No.: HY-110063
CAS No.: 41270-96-6
Purity:  99.46%
Synonyms: 4-Iodo-6-phenylpyrimidine
4-IPP (4-Iodo-6-phenylpyrimidine) is a specific suicide substrate and irreversible inhibitor of macrophage migration inhibitory factor (MIF) .
loading...
    loading...
10
10 Cited Publications
Cat. No.: HY-P7424
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: rHuRANK L/TNFSF11; TRANCE; CD254
Species:  
Source:  
loading...
    loading...
8
8 Cited Publications
Cat. No.: HY-113556
CAS No.: 102067-84-5
Purity:  99.87%
Sappanone A is an orally active homoisoflavone found in sappan L. Sappanone A is a PDE4 and NF-κB inhibitor with anti-inflammatory and antioxidant effect. Sappanone A induces HO-1 expression through activation of Nrf2 pathway. Sappanone A also inhibits RANKL-induced osteoclastogenesis. Sappanone A has great potential in the research of inflammation-related and cardiovascular .
loading...
    loading...
7
7 Cited Publications
Cat. No.: HY-17408
CAS No.: 73573-88-3
Synonyms: Compactin; ML236B
Mevastatin (Compactin) is a first HMG-CoA reductase inhibitor that belongs to the statins class. Mevastatin is a lipid-lowering agent, and induces apoptosis, arrests cancer cells in G0/G1 phase. Mevastatin also increases endothelial nitric oxide synthase (eNOS) mRNA and protein levels. Mevastatin has antitumor activity and has the potential for cardiovascular diseases treatment .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-B1246
CAS No.: 553-08-2
Target:  

Bacterial Proton Pump

Research Areas:  

Infection

Thonzonium bromide is an antibacterial agent that is structurally similar to Farnesol (HY-Y0248A). Thonzonium bromide is also a monocationic surface-active agent, which inhibits RANKL-induced osteoclast formation and bone resorption in vitro and prevents LPS-induced bone loss in vivo. Thonzonium bromide inhibits proton transport in a dose-dependent manner (EC50=69 μM) .
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-P73388
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Tumor necrosis factor ligand superfamily member 11; rankl; CD254; ODF; OPGL; TNFSF11; TRANCE
Species:  
Source:  
loading...
    loading...
6
6 Cited Publications
Cat. No.: HY-N0762
CAS No.: 31524-62-6
Isobavachin is an orally active, blood-brain barrier-penetrating prenylated flavonoid present in Psoralea corylifolia. Isobavachin inhibits human CYP2B6, CYP2C9, CYP2C19, UGT1A1, UGT1A9, and UGT2B7. Isobavachin suppresses MAPK activation, NF-κB nuclear translocation, overexpression of iNOS/COX-2, FcεRI-mediated signaling pathways, and RANKL-induced osteoclastogenesis. Isobavachin induces autophagy, cytotoxicity, neuronal differentiation, and NRF2 activation; it alleviates oxidative damage, inflammatory responses, apoptosis, iron accumulation, mitochondrial biogenesis, and mast cell degranulation. Isobavachin is applicable to research related to liver injury, inflammatory diseases, osteoporosis, liver cancer, prostate cancer, glioma, periodontitis-induced bone loss, and Alzheimer's disease .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-N2119
CAS No.: 521-34-6
Sciadopitysin is a type of biflavonoids in leaves from ginkgo biloba . Sciadopitysi inhibits RANKL-induced osteoclastogenesis and bone loss by inhibiting NF-κB activation and reducing the expression of c-Fos and NFATc1 .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-147369
CAS No.: 1912422-56-0
Purity:  99.97%
Research Areas:  

Others

NFATc1-IN-1 (compound A04) is a potent inhibitor of RANKL-induced osteoclast formation, with an IC50 of 1.57 μM. NFATc1-IN-1 shows anti-osteoclastogenic effects through reducing the RANKL-induced nuclear translocation of NFATc1. NFATc1-IN-1 can be used for osteoclastic diseases research .
loading...
    loading...
4
4 Cited Publications
Cat. No.: HY-P73386
Purity:  ≥ 90%, as determined by reducing SDS-PAGE.
Synonyms: Tumor necrosis factor ligand superfamily member 11; rankl; CD254; ODF; OPGL; TNFSF11; TRANCE
Species:  
Source:  
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9958
CAS No.: 615258-40-7
Synonyms: AMG-162

Research Areas:  

Endocrinology Cancer

Denosumab is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-110318
CAS No.: 1785665-61-3
Purity:  98.28%
Target:  

CXCR

Research Areas:  

Inflammation/Immunology Cancer

VUF11207 fumarate is a CXCR7 agonist that binds specifically to CXCR7. VUF11207 fumarate reduces CXCL12-mediated osteoclastogenesis and bone resorption by inhibiting ERK phosphorylation .
loading...
    loading...
3
3 Cited Publications
Cat. No.: HY-P9958A
CAS No.: 615258-40-7
Denosumab (anti-TNFSF11) is a human monoclonal antibody that targets the protein RANKL. Denosumab binds to the receptor activator of nuclear factor kappa-B ligand (RANKL) and prevents its binding to the RANK receptor (KD of 0.003 nM for human RANKL). Denosumab promotes proliferation and spermatogenesis. Denosumab prevents bone resorption through inhibition of the NF-κB pathway. Denosumab can be used in bone-related studies .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0277
CAS No.: 509-20-6
Synonyms: Jesaconine
Aconine inhibits receptor activator of nuclear factor (NF)-κB ligand (RANKL)-induced NF-κB activation.
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N1419
CAS No.: 53452-16-7
Vaccarin is an orally active flavonoid glycoside with multiple biological functions. Vaccarin promotes neovascularization by activating AKT and ERK. Vaccarin activates the AMPK signaling pathway to improve insulin resistance and steatosis. Vaccarin is a MAPK, NF-κB, and NFAT inhibitor, effectively blocking RANKL-induced osteoclastogenesis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-W008634
CAS No.: 56741-95-8
Synonyms: U-54461; U-54461S; PNU-54461
Research Areas:  

Cancer

Bropirimine (U-54461; U-54461S; PNU-54461) is an orally active TLR7 agonist. Bropirimine inhibits RANKL-induced osteoclast differentiation of mouse bone marrow-derived macrophages (BMMs). Bropirimine exhibits dose-dependent direct inhibitory effects on colony formation of cultured KK-47 and 724 cells. Bropirimine can be used for the study of cancers and bone metabolic disorders such as osteoporosis .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0656
CAS No.: 125-46-2
Usnic acid is a secondary metabolite of lichens with a unique dibenzofuran skeleton. Usnic acid inhibits DNA/RNA synthesis and has antibacterial activity. Usnic acid induces cell cycle arrest and apoptosis and has anticancer activity. Usnic acid inhibits RANKL-mediated osteoclast formation and function by reducing the transcriptional and translational expression of NFATc1. Usnic acid has antioxidant and anti-inflammatory activities by inhibiting lipid peroxidation and myeloperoxidase .
loading...
    loading...
2
2 Cited Publications
Cat. No.: HY-N0026
CAS No.: 94492-24-7
Synonyms: 2'-AA
2'-Acetylacteoside (2'-AA) is a natural compound with oral activity and blood-brain barrier permeability. 2'-Acetylacteosideexhibits MAO‑B inhibitory activity (IC50 = 17.71 μM, Ki = 13.81 μM). 2'-Acetylacteoside downregulates the expression of RANK, TRAF6, NF‑κB, NFATc1 and IKKβ, disrupts the RANKL/RANK interaction, blocks downstream signaling pathways, and increases the level of phosphorylated Akt. 2'-Acetylacteoside possesses potent anti-osteoclastogenic, anti-bone resorptive, pro-neurogenic, neuroprotective and antioxidant activities. 2'-Acetylacteoside can be used in the research of osteoporosis, ischemic stroke and Parkinson's disease .
loading...
    loading...